Skip to main content

Protection provided by vaccine

The COVID-19 vaccines approved in the EU provide efficient protection especially against the most serious forms of the disease. The pharmaceutical companies developing vaccines have had to do very careful research before the vaccine has been given marketing authorisation.

The COVID-19 virus causes an acute respiratory infection, where the clinical picture can vary from asymptomatic to very severe, even requiring intensive care. Additionally some patients may suffer from long-term consequences, like fatigue, bronchoconstriction, cough as well as pain in the joints or thorax. COVID-19 vaccines prevent the severe form of the illness effectively and decrease the risk of hospitalization and long-term consequences. The vaccines also somewhat prevent infections.

COVID-19 infections occur despite vaccines, but vaccinated people get probably milder infections than those without vaccination. The vaccine gives a clearly better and more long-lasting protection against severe disease than against the infection itself.

The COVID-19 virus is constantly transforming, and therefore the efficacy of the vaccines against the new virus variants and infections is monitored continuously. The COVID-19 vaccines provide fairly good protection against the new COVID-19 variants so far recognised, but the protective efficacy may by weaker against certain variants. Lately COVID-19 vaccines have been developed that are tailored against a particular variant of the virus. However, more research is needed and is being conducted constantly.

Further reading

Page published 28.04.2021 | Page edited 31.10.2023